A Phase 1/2 clinical study to evaluate the safety and efficacy of CG0070, in combination with OPDIVO (nivolumab), for the treatment of metastatic urothelial cancer
Latest Information Update: 15 Sep 2021
At a glance
- Drugs Cretostimogene grenadenorepvec (Primary) ; Nivolumab (Primary)
- Indications Urogenital cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors CG Oncolgy
- 15 Sep 2021 New trial record